Mitoguazone

Mitoguazone
Clinical data
Other names	2-[[(1E)-1-(Diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
ATC code	L01XX16 (WHO) ;
Identifiers
	IUPAC name (2E,2'E)-2,2'-(1E,2E)-propane-1,2-diylidenedihydrazinecarboximidamide;
CAS Number	459-86-9 ;
PubChem CID	5351154;
ChemSpider	4508218 ;
UNII	OD5Q0L447W;
KEGG	D07258 ;
ChEBI	CHEBI:43996 ;
CompTox Dashboard (EPA)	DTXSID70861943 ;
ECHA InfoCard	100.121.515
Chemical and physical data
Formula	C5H12N8
Molar mass	184.207 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C\C(\C=N\NC(N)=N)=N/NC(N)=N;
	InChI InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+ ; Key:PKDBCJSWQUOKDO-UHFFFAOYSA-M ;
	(what is this?) (verify)

Mitoguazone (also known as methylglyoxal bis(guanylhydrazone) or MGBG) is a drug used in chemotherapy.^[1]

References

^ Hoffmann H, Gutsche W, Amlacher R, Schulze W, Werner W, Lenk H, Wohlrab W, Haupt E (1989). "[Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects]". Archiv für Geschwulstforschung (in German). 59 (2): 135–48. PMID 2655552.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.